BRABIO

This brand name is authorized in Ireland, United Kingdom

Active ingredients

The drug BRABIO contains one active pharmaceutical ingredient (API):

1 Glatiramer UNII U782C039QP - GLATIRAMER

Glatiramer is presumed to involve modulation of immune processes. Glatiramer is licensed for reduced frequency of relapses in relapsing-remitting multiple sclerosis. Read about Glatiramer

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
BRABIO Solution for injection	Medicines & Healthcare Products Regulatory Agency (GB)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
L03AX13	Glatiramer acetate	L Antineoplastic and immunomodulating agents → L03 Immunostimulants → L03A Immunostimulants → L03AX Other immunostimulants
Discover more medicines within L03AX13

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: GB	Medicines & Healthcare Products Regulatory Agency	Identifier(s): 348078, 350413
Country: IE	Health Products Regulatory Authority	Identifier(s): 88774, 88884